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This work reports the purification of  new potent scorpion neuropeptide, named BotAF,  by an activity- 
guided screening approach. BotAF is a  64-residue long-chain peptide that shares very high similarity 
with the original b-like scorpion toxin group, in which several peptides have been characterized to be 
anti-nociceptive in rodents. BotAF administration to rodents does not produce any toxicity or  motor 
impairment, including at  high doses. In  all  models investigated, BotAF turned out to be  an  efficient 
peptide in abolishing acute and inflammatory (both somatic and visceral) pain in rodents. It performs 
with high potency compared to standard analgesics tested in the same conditions. The anti-nociceptive 
activity of  BotAF depends on the route of  injection: it is inactive when tested by i.c.v.  or  i.v.  routes but 
gains in potency when pre-injected locally (in the same compartment than the irritant itself) or  by i.t. 
root 40  to 60 min before pain induction, respectively. BotAF is not an  AINS-like compound as  it fails to 
reduce inflammatory edema. Also, it does not activate the opioidergic system as its activity is not affected 
by naloxone. BotAF  does also not bind onto RyR and has low activity  towards  DRG  ion channels 
(particularly TTX sensitive Naþ  channels) and does not bind onto rat  brain synaptosome  receptors. In 
somatic and visceral pain models, BotAF  dose-dependently  inhibited lumbar spinal cord c-fos/c-jun 
mRNA up regulation. Altogether, our data favor a spinal or  peripheral anti-nociceptive mode of  action of 
BotAF. 
 
 
 
 
 
1.   Introduction 
 
Animal venoms are  reliable sources for  drug discovery and 
implementation of new pharmaceutical tools (Attarde et al., 2016). 
The richness and complexity in venom composition is the result of 
Darwinian selection forces onto several genes constituting families 
of  coding toxins. As a  result of  this evolutionary pressure, the 
selected natural compounds act  on  an  as  diverse number of  bio- 
logical targets that include ion   channels, G-protein coupled re- 
ceptors, transporters and enzymes. Most  often, these venom 
components bind with exquisite selectivity and potency on their 
receptors making venom-derived components highly attractive 
pharmacological tools and possible drug leads. The usefulness of 
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venomous compounds as  analgesics has been validated in  several 
preclinical studies. This is the case of the following compounds: u- 
conotoxin MVIIA  (ziconotide) (Essack et al.,  2012),  p-Ther- 
aphotoxin-Pc1a (PcTx1) (Escoubas et al., 2003), APETx2 from a sea 
anemone species (Jensen et al., 2014), and long neurotoxin OH-55 
(hannalgesin) (Pu et al., 1995).  These analgesic compounds  arise 
from different venom sources and species (conus, snake, sea 
anemone, spiders) and were discovered by using diverse screening 
strategies as  well (target-based, toxin-based and activity-based). 
While many anti-pain compounds have been identified so far, 
ziconotide remains the only toxin-derived therapeutic for  pain 
treatment that reached the clinics. This difficulty in  converting 
preclinical leads into therapeutics  may be  the reflection of  two 
major challenges: i) reaching proper potency and selectivity and ii) 
providing proper target accessibility and coverage. Part  of  these 
challenges may be met by further discovering novel compounds or 
simply by improving the potency, selectivity and delivery of known 
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anti-pain toxins. As such, expanding the screening efforts to scor- 
pion venom toxins may represent a promising approach. To  date, 
most of  the investigators interest has focused on  long-chain 
insectotoxins  based on   the  assumption  that  they  should  lack 
toxicity in  mammals and on  the well-documented  analgesic po- 
tential  of   their  targeted  sodium  channels  in   pain  physiology. 
Indeed, this is the case for  BmKIT2 (Guan et al., 2001), BmkAS (Cui 
et al.,  2010),  LqqIT2 (Martin-Eauclaire et al.,  2010) and BmKAEP 
(Wang et al., 2011). These compounds are  purified by an  in  vivo 
screening approach of  abundant venom compounds (or  at  least 
highly active compounds) checking for  phenotypic or  behavioral 
changes. Relevant compounds isolated this way are  further inves- 
tigated for  identifying their molecular targets and for  assessing 
their pharmacodynamics by in  vitro approaches. While  target- 
based drug discovery allows for  the identification of  new molecu- 
lar tools of  interest in  pharmacology, it may end up  providing 
frustrating results in vivo because of  the complexity of  pain etiol- 
ogy,   the  challenges faced with  the  pharmacokinetics and the 
importance of   the mode of  administration, with  or  without 
adequate formulation. In  contrast, compounds  isolated against a 
rigorously defined in  vivo pain model should deliver compounds 
that  meet  the  criteria of   preclinical evaluation, with  yet  un- 
certainties regarding the mode of action and the molecular target. 
The main advantage nevertheless remains that the compounds 
isolated through phenotypic assays will be  more easily character- 
ized with regard to the pharmacodynamics parameters (efficacy, 
potency, delivery…). 
Herein, we used an  activity-guided screening strategy to iden- 
tify a venom compound from a Tunisian scorpion using an  in vivo 
rodent pain model. We performed a double in  vivo screening by 
assessing both toxicity  and analgesia of  the fractionated venom 
compounds. Next, we investigated some of its basic pharmacolog- 
ical properties in vivo by using standardized pain models and ruled 
out some possible anti-nociceptive molecular targets. 
 
2.  Materials and methods 
 
2.1.   Animals 
 
All anti-nociceptive experiments were conducted on  healthy 
adult male C57/BL6 mice (25e30 g)  and adult female Whistar rats 
(180e220 g). For  toxicity tests, male C57/BL6 mice (18e22 g)  were 
used. Animals were housed at a density of 6 per  cage and had free 
access to food and water in a quiet environment. The room was 
maintained at  21e23 o C with a 12 h light/dark cycle. The experi- 
menter was blind to the pharmacological treatment. All animal 
procedures were reviewed and approved by the Ethics Committee 
of the Pasteur Institute of Tunis according to the guidelines on  the 
use of  living animals in  scientific investigations. All efforts were 
made to minimize both the suffering and number of animal used. 
 
2.2.  Purification procedure 
 
120 ml of  crude venom of  the scorpion Buthus occitanus tune- 
tanus (Bot) was obtained by electrical milking of  field-collected 
scorpions at  the Veterinarian Laboratory of  the Institute Pasteur 
of  Tunis. This crude venom of  Bot was water extracted, then sub- 
mitted to gel  filtration chromatography on  Sephadex G50 columns 
(2 x K26/50, GE Healthcare, France) equilibrated with 0.1 M acetic 
acid.   Five fractions (MI,  MII, BotG50, III  and VI) were resolved. 
Fractions MII and BotG50 were lyophilized, resuspended in  water 
and further fractionated by a reversed-phase HPLC (Hew- 
lettePackard Series II 1100 liquid chromatography with diode array 
UV  detection) equipped with  a   semi-preparative C8  column 
(10 mm x 250 mm,   5 mm,    Beckman   Fullerton,   USA).    For    this 
purpose, buffer A was 0.1% trifluoroacetic acid in water and buffer B 
was 0.1%  trifluoroacetic acid (TFA) in  acetonitrile. The column ef- 
fluents were monitored at 280 and 214 nm. Peptide fractions were 
eluted at 1 mL/min in a linear gradient of buffer B in buffer A and at 
fixed 25 o C temperature. Fraction F28, was loaded onto an  analyt- 
ical   C18  reversed-phase HPLC column (10 mm x 250 mm, 5 mm, 
Beckman Fullerton, USA) using a linear gradient of buffer B in buffer 
A allowing the isolation of  BotAF.  Protein concentration  was 
measured by amino-acid analysis. 
 
2.3.  Mass spectrometry 
 
Samples were analyzed on  a Voyager-DETM  PRO MALDIeTOF 
(matrix-assisted laser-desorption ionizationetime-of-flight) 
Workstation mass spectrometer (Perceptive Biosystems, USA). The 
peptide was dissolved in 30% acetonitrile with 0.3% TFA to obtain a 
concentration of  1e10 pmol/mL.  The matrix was prepared as  fol- 
lows: a-cyanohydroxycinnamic acid was dissolved in  50%  aceto- 
nitrile in 0.3% TFA/H2O to obtain a saturated solution at 10 mg/mL. A 
0.5 mL  of  peptide solution was then mixed with 0.5 mL  of  matrix 
solution  and placed on   the sample plate, and the mixture was 
allowed to dry. Mass spectra were recorded in reflectron mode after 
external calibration with  suitable standards and were analyzed 
using the GRAMS/386 software (Galactic Industries Corporation). 
 
2.4.  Reduction and  alkylation of peptide 
 
Five nanomoles of  BotAF was dissolved in  40 mL  of  alkylation 
buffer (6 M guanidine HCl, 0.5 M Tris/HCl, 2 mM EDTA,  pH 7.5) 
containing 1.4 mmol  dithiothreitol (DTT). After 1 h of  reduction at 
37 o C, 9 mmol  of  4-vinylpyridine (4-VP) was added for  alkylation. 
The S-alkylated BotAF (SA-BotAF)  was then desalted by dialyze 
against  10%   acetic  acid  at   4 o C  overnight  using  Spectra/Por 6 
membrane tubing with a 4000 MW cut-off (Spectrum Laboratories 
Inc., USA). The dialyzed product was then subjected to SDS-PAGE on 
a 15% gel  and then revealed by Coomassie Blue staining. 
 
2.5.  In-gel digestion of alkylated BotAF by trypsin and  S. aureus V-8 
protease 
 
The in-gel digestion of  SA-BotAF was performed as  previously 
described (Jeno€  Paul   et al., 1995).  Briefly,  SDS-PAGE gel  protein 
bands were excised after Coomassie Blue distaining, then washed 
with 40% n-propanol followed by 0.2 M NH4HCO3/50% acetonitrile, 
and finally dried in Speed Vac. Gel pieces were rehydrated in 100 mL 
of  100 mM NH4C03 pH 7.8  containing 1 mg trypsin or  S. aureus V8 
protease. After 24 h of  digestion at  37 o C, peptide fragments were 
extracted three times from the gel  slices with three consecutive 
treatments:  first, 200 mL  of  0.1%  TFA,  0.01%   Tween 20; second, 
100 mL of 1% TFA, 0.01%  Tween 20; and third, 100 mL of 0.1% TFA, 50% 
acetonitrile, 0.01%  Tween20 (Eckerskorn and Lottspeich, 1990). 
Enzymatic digests were separated by high-performance liquid 
chromatography on  an  analytical C18 reverse phase HPLC column. 
 
2.6.  Amino acid  sequencing and  sequence analyses 
 
The amino acid sequences of the N-terminal fragment and of the 
peptides derived from proteolytic digests of SA-BotAF were deter- 
mined by an   automatic liquid-phase protein sequencer (model 
476A,  Applied Biosystems, USA)  using a standard Edman protein 
degradation procedure (Edman and Begg, 1967). Search for proteins 
homologous to BotAF was performed using the NCBI  BLAST data- 
base search program implemented  at  the web site (http://www. 
ncbi.nlm.nih.gov/). The amino acid sequence  of  BotAF was aligned 
with other toxins using Clustal W (Thompson et al., 1994) running 
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in BioEdit version 7.2.6  (Hall, 1999). 
 
 
 
2.7.  Cloning of BotAF isoforms 
 
Total RNA were extracted from homogenized Bot  scorpion tel- 
sons, containing venomous glands, using the RNAgents  kit  from 
Promega (Madison, WI, USA).  5  Bot  scorpions were used for  this 
purpose. Single stranded cDNA  was obtained by reversed- 
transcription  using  an    universal  oligo(dT)-containing  adapter 
primer    (50 -GGCCACGCGTCGACTAGTAC(dT)17-3
0 ,    Proligo).   The 
following reaction mixture: 12 mL of DEPC (diethylpyrocarbonate)- 
treated water containing 0.1 mg of  primer and 1 mg of  total venom 
gland RNA, 2 mL of 0.1 M DTT, 1 mL of RNAsin (ribonuclease inhibitor 
at 40 units/mL from Promega), 1 mL of dNTP (10 mM each, Promega) 
and 200 units  of  M-MLV RT  (Moloney  murine leukaemia virus 
reverse transcriptase). The final volume was adjusted to 20 mL, and 
the reaction mixture was incubated at  37 o C for  1 h,  followed by 
10 min at 95 o C to inactivate the enzyme. At the end of the reaction, 
RNAse H was added to degrade mRNA. 
Next, cDNA sequence encoding BotAF analogues were amplified 
by PCR using venom gland cDNA  as template and the following 
primers: a  forward primer corresponding to a  degenerated 
sequence            (50 -GAT-AA(T/C)-GGT-TA(T/C)-GT(N)-CTT-GAC-30 ) 
derived from the N-terminal peptide sequence of  BotAF and also 
based  on   the cDNA  sequence homology of   three  homologous 
peptides of  BotAF (BmKAS, BmKAS1  and BotIT2), and a  reverse 
primer (50 -GGC-CAC-GCG-TCG-ACT-AGT-AC-30 ),  corresponding to 
the universal amplification primer used for  cDNA  synthesis. The 
PCR protocol included an initial denaturizing step at 95 o C for 2 min 
followed by 35  cycles of  denaturation (30 s at 94 o C), annealing 
(30 s at 52 o C) and extension (30 s at 72 o C), and a final extension for 
7 min at 72 o C. 
The amplified fragments were separated on  1% agarose gel 
electrophoresis. Desired bands were excised under UV-light  and 
purified using the Gel Extraction Kit (QIAGEN) and were cloned into 
pGEM-T   vector  (Promega). Positive recombinant clones  were 
confirmed by PCR-amplification and sequencing. 
 
 
 
2.8.  Toxicity test and  rotarod test 
 
BotAF was tested for  in vivo toxicity on  20 ± 2 g male mice C57/ 
BL6   by intracerebroventricular (i.c.v.) injection of  7 mL  of  saline 
solution containing increasing amounts of  the peptides. Six mice 
were used for  each concentration. Behavioral parameters consid- 
ered as signs of  toxicity were: tremors, convulsions, paralysis, up- 
ward tail  and fur,  abnormal gait  and posture (Clot-Faybesse et al., 
2001; Galeotti et al., 2003). Mortality was assessed 48 h after i.c.v. 
administration. 
Accelerating rotarod test (Jones and Roberts, 1968) was assessed 
prior to pain behaviors study to further check if there is any motor 
impairment due to BotAF injection. The rotarod apparatus (Ugo 
Basile Biological Research Apparatus, Varese, Italy) is used as 
described  (Plummer  et  al.,  1991).  Briefly,   male  C57/BL6 mice 
(18e22 g) were placed on the rod  when it was rotating at a speed of 
2.5 rpm. After 10 set,  the timer was started and the speed of the rod 
was increased (2.5e25 rpm over 5 min). Four BotAF-treated groups 
(6 mice per  group) were tested: (1, 2 mg/kg) i.p. and (0.2, 0.5 mg/kg) 
i.t.. The drop latency for  each tested animal groups was recorded 
before, 30 min, and 60 min after treatments. Evaluation of  BotAF 
action on  motor impairment was assessed by comparing, for  each 
group, the drop latency recorded before and 30 min or 60 min after 
treatment. 
2.9.  Intrathecal injection 
 
Intrathecal administration was done by a  direct injection on 
conscious rat and mice as described previously (Mestre et al., 1994). 
Briefly,  the injections were performed by a  25-Ga x 100   needle, 
connected to a 25-1xL Hamilton syringe, into the tissues between 
the dorsal aspects of  L5  and L6,  perpendicular to the vertebral 
column. This site was selected so that the injection was restricted to 
the region where the spinal cord ends and the cauda equina begins 
in order to reduce the possibility of spinal damage and increase the 
intervertebral accessibility.  The syringe was held in  position for  a 
few seconds and progressively removed to avoid any outflow of the 
drug. 
 
2.10.   Pain  models 
 
All injected drugs were dissolved in  saline. Volumes for  mice 
injection were: 7 mL by i.c.v., 150 mL intraperitoneally (i.p.), 15 mL by 
intrathecal route (i.t.)  and 50 mL by intraplantar (i.pl.). Each animal 
was tested only once and sacrificed thereafter. Several pain models 
were used: the hot-plate test, the writhing test, the tail  flick  test 
and the formalin test, as briefly described hereunder. 
The writhing test consists of an i.p. injection of acetic acid (0.6%, 
7.5 mg kg-1)  to mice pretreated at  different time before with the 
compounds of interest. Results are  presented as inhibition percent 
of  the contortion numbers that occur during 30 min following the 
injection of acetic acid (Collier et al., 1968). 
For the hot-plate test, mice are  placed into a  glass cylinder 
(14 cm diameter and 20 cm height) on a hot-plate adjusted to 55 o C 
(hot-plate analgesia meter, Harvard Apparatus, USA). The latency of 
the hind paw licking was used as an  index of pain reaction. A 60 s 
cut-off was used to preserve the physical integrity of  the animal. 
Concerning the tail flick  test, the apparatus consists of a shutter- 
controlled lamp as a heat source (tail flick  analgesia meter, Harvard 
Apparatus, USA).  The test was performed as  described previously 
(D'Amour and Smith, 1941). Briefly, the tail of the mice was marked 
at a distance of 2 cm from the apex and was placed under the heat 
source. The time taken by the treated animal to flick  its tail  was 
recorded. A cut-off of 60 s was used to respect animal integrity. 
For the formalin test, 50 mL of 5% formalin was administered i.pl. 
into the left hind paw. Each rat  was placed individually in  a plexi- 
glass test box for  at  least 30 min to adapt to the new environ- 
ment before administration of  the chemical agents. Nociceptive 
behaviors were determined by counting the time spent in  liking 
and flinching the injected hind-paw over consecutive periods of 
5 min during 1 h following formalin injection. Data collected be- 
tween 0 and 10 min post-formalin injection compose phase 1, and 
data collected between 15 and 60 min post-formalin injection 
represent phase 2 (Abbott et al., 1995). 
 
2.11.   Volume changes of rat hind paw inflammation 
 
Paw edema was induced by injection of  100 mL of  carrageenan 
(final concentration 15 mg/kg) into the rat left hind paw.  Edema 
was followed by measuring changes in  paw volumes using a ple- 
thysmometer  (Ugo Basile, Italy) at  various times (0, 1,  2, 3, 4 and 
5 h).  Before carrageenan treatment, the rats receive in the same 
paw an injection of vehicle, dexamethasone (100 mL, 1 h before) or 
BotAF (20 min before) at concentrations as indicated in the text. The 
increase in paw volume is considered as an  index of inflammation 
intensity (Di ROSA and Sorrentino, 1968). To  measure paw volume 
fluctuation, the injected hind paw was immersed into a water cell 
filled with a solution of  0.04e0.05%  NaCl according to manufac- 
turer's instructions, and the volume of  spillage considered as  the 
volume of hind paw. 
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2.12.   Analyses of c-fos/c-jun expression profiles 
 
Lumbar spinal cords were quickly removed by syringe aspiration 
after decapitation of mice (n ¼ 3 per  group), 3 h after drugs or saline 
(control) administration and put immediately in  nitrogen before 
mRNA  extraction. Total RNA  were prepared from mouse spinal 
cords using Macherey-Nagel Kit (NucleoSpin  RNA  II)  and were 
converted  in   cDNA  using First Strand cDNA  Synthesis kit   (GE 
Healthcare). Transcripts from c-fos or  c-jun were quantified using 
TaqMan probes obtained from Applied Biosystems (Foster City, Ca). 
Calculations were performed using mRNA  c-fos or  c-jun/mRNA 
glyceraldehyde 3 phosphate dehydrogenase (GAPDH) ratio. GAPDH 
was chosen as a house keeping gene. 
 
2.13.   Electrophysiological study 
 
Adult rat DRG neurons were isolated and cultured according to 
the method described by Herzog et al.  (2003).  Briefly,  rats were 
anesthetized and decapitated. Cells were treated with collagenase 
(1 mg/mL) and papain (1 mg/mL), dissociated in  DMEM  supple- 
mented with 10% fetal bovine serum, and plated on glass coverslips 
coated with poly-L-ornithine and laminin. Cultures  were main- 
tained at 37 o C in a 5% CO2 incubator, and media was changed every 
2 days during experimental incubation periods. DRG neurons ex- 
press both tetrodotoxin-sensitive (TTX-S) and TTX-resistant (TTX- 
R)  sodium channels. 
Whole-cell   recordings  were  performed  on    DRG  neurons. 
Membrane currents were measured with pipettes (2e5 MU) pulled 
from glass capillary tubes and connected to an  EPC-9 amplifier 
operating Pulse:Pulsefit software (HEKA elektronik, Germany). The 
pipette solution was composed of  (in mM): CsCl 120,  TEACl  20, 
Na2ATP 5, EGTA 10, HEPES 10, MgCl2 2.5, Na2GTP 0.4. The pH of the 
solution was adjusted to 7.3  with CsOH. The external solution was 
composed of (in mM): NaCl 140, KCl 5, CaCl2 2.5, MgCl2 1, HEPES 10, 
D-glucose 10. The solution was adjusted to pH 7.3e7.4 with NaOH. 
Ag-AgCl  saline bridge was used for  the reference electrode. The 
peak sodium currents were selected out and normalized by their 
relative amplitude to control. 
 
2.14.   Iodination of BotAF and  synaptosome preparation 
 
BotAF was iodinated by the lactoperoxidase method of  [125I] 
iodide oxidation according to Rochat et al.  (1970).  The specific 
radioactivity was found to be  200 Ci/mmol. The native BotAF was 
tested for its ability to displace [125I]-BotAF from the binding site of 
synaptosome P2  preparations (Gray and Whittaker, 1962). Synap- 
tosomes (3.3 mg/mL) were  incubated  in   a  medium  containing 
130 mM  choline chloride, 5.4 mM  KCl, 5.5 mM glucose,   0.25% 
bovine serum albumin, 50 mM HEPES, pH 6.5;  0.2 nM [125I]- BotAF 
and increasing concentrations  of  BotAF were then added. After 
30 min at 37 o C, the synaptosomes were centrifuged (11,000 x g for 
1 min), the residual pellets were washed twice with the same 
medium  and the bound radioactivity measured. The values are 
means of duplicate determination. 
 
2.15.   Effect of BotAF on  [3H]-ryanodine binding to SR  vesicles 
 
SR vesicles from rabbit muscles were prepared as  described 
previously in  Marty et al. (2000).  For the [3H]-ryanodine binding 
assay, heavy SR vesicles (1 mg/mL) were incubated at 37 o C for  3 h 
in an assay buffer composed of 5 nM [3H]-ryanodine, 150 mM NaCl, 
2 mM EGTA, 2 mM CaCl2 (pCa ¼ 5), and 20 mM HEPES, pH 7.4. BotAF 
was added to the assay buffer just prior the addition of  heavy SR 
vesicles. [3H]-ryanodine bound to heavy SR vesicles was measured 
by filtration through Whatmann GF/B glass filters followed by three 
washes with 5 mL of ice-cold washing buffer composed of 150 mM 
NaCl, 20 mM HEPES, pH 7.4. Filters were then soaked overnight in 
10 mL scintillation cocktail (Cybscint, ICN) and bound radioactivity 
determined by scintillation spectrometry. 
 
2.16.   Statistical analyses 
 
Statistics  and determination of  ED50  values were done using 
GraphPad Prism®  (version 4.02,  GraphPad, San Diego, CA). The re- 
sults are expressed as mean ± S.E.M with the exception of the ED50 
value (the dose of compound that produces 50% of  the effect rela- 
tive to the control value) value, which was reported as the geo- 
metric mean accompanied by respective 95%  confidence limits. 
ED50  values were determined by non-linear regression analysis 
using a sigmoid dose-response equation. Ratios were considered 
significant if the confidence interval did  not overlap. N ¼ 6 animals 
for each dose of compound used in all tests. The level of significance 
was set at 5% (P < .05),  and denoted by one *. 
 
3.  Results 
 
3.1.   Purification of a new analgesic peptide from Bot  venom 
 
120 mL of scorpion Bot venom was water extracted, centrifuged 
and the supernatant was fractionated using gel  filtration chroma- 
tography on  Sephadex G50 (Miranda et al., 1970).  Five fractions 
were resolved: MI, MII, BotG50, III and IV (Fig. 1A). Fractions were 
lyophilized and resuspended in  water at  0.3 mg/mL. Toxicity assays 
were performed on  mice by i.c.v.  injection of  0.1 mg/kg or  by i.p. 
administration of  5 mg/kg of  each fraction.  At this concentration, 
fractions MI, MII, III  and IV were non-toxic in  opposition to 
BotG50wich was lethal. These fractions were tested for their ability 
to induce analgesia in mice using the writhing test. Fractions were 
injected i.p.  at  5 mg/kg and evaluated  for  analgesia 1 h later.  As 
shown, only fraction MII displayed a significant decrease in 
abdominal writhes  (Fig. 1B).  Next, the MII fraction was further 
fractionated by reversed-phase C8 semi-preparative HPLC (Fig. 1C). 
Among the collected fractions, only fraction F10 i.p. administrated 
at  5 mg/kg (arrow in  Fig.  1C) displayed analgesic effect using the 
writhing test (Fig. 1D). At this stage, two factors prevented further 
characterization of the active peptide: (i) a poorly resolved peak as 
determined by C8 HPLC and (ii)  the fact that the F10 fraction is only 
a minor component of the MII fraction. To solve this issue, we next 
determined whether a fraction similar to F10 in terms of  elution 
profile may be  present also in  the BotG50 fraction, which seemed 
possible because of the partial overlap in MII and BotG50 fractions 
(Fig. 1A). As shown by the HPLC profile of  the BotG50 fraction, a 
fraction that presents similar characteristics to F10 is also present in 
the BotG50 fraction, but in  greater amounts and with better reso- 
lution (Fig. 1E). In BotG50 C8 chromatographic profile F10 appears 
as a pool of smaller fractions defined as FI, F28, FIII, FIV and FV,  that 
were all further evaluated for  their toxicity in  mice. None of  these 
smaller fractions were toxic up to 0.1 mg/kg by i.c.v. and 5 mg/kg by 
i.p.  route which permitted their evaluation for  the writhing test 
pain model. Of all these fractions tested, only F28 has the ability to 
attenuate  abdominal contortions  in  mice upon i.p.  injection  at 
2 mg/kg (Fig. 1F). When further resolved on  an analytical reversed- 
phase C18 column, F28 eluates as  a single well-resolved peak at a 
fixed retention time of  14 min encompassing a molecule that we 
termed  BotAF  for   Buthus  occitanus  tunetanus  Analgesic  Factor 
(Fig. 1G). In this elution profile, other minor contaminants were also 
present. Intraperitoneal pretreatment of mice with 2 mg/kg of pu- 
rified BotAF was sufficient to attenuate up  to 85%  of  abdominal 
cramps, whereas injection, in  same experimental conditions, of  a 
collected  pool  of   the  contaminants,  had  no   effect  (Fig.  1H). 
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Fig. 1.  Purification of BotAF, a new analgesic peptide, from Bot  venom. (A) Gel filtration chromatography of water-extracted Bot  venom defining five fractions (line illustrations). (B) 
Anti-nociceptive effect of  each Sephadex G50 fraction using the writhing test model. i.p.  injection at  5  mg/kg, test  1 h after fraction injection. (C) Reversed-phase C8 semi- 
preparative HPLC fractionation of  MII fraction. Elution of  F10 fraction is indicated by a continuous line. Gradient starting at  20%  buffer B  and evolving with a gradient of  0.7% 
buffer B/min. (D) Anti-nociceptive effect of  each peak eluted in (D) using the writhing test model. With i.p.  injection at  5 mg/kg for  each peak, and test 1 h after treatment. (E) 
Reversed-phase C8 semi-preparative HPLC fractionation of  BotG50 fraction. A fraction similar to F10 in terms of  elution profile is also indicated, and the presence of  five smaller 
fractions indicated (FI,  F28, FIII,  FIV and FV). Similar elution conditions as  in (C). (F) Anti-nociceptive effect of  each peak defined in (D) using the writhing test model. With  i.p. 
injection at  2 mg/kg for  each peak, and test 1 h after treatment. (G) Analytical C18-HPLC chromatogram of  F28 fraction showing the presence of  a well-resolved major peak and 
some minor contaminants. Elution was performed starting using a linear 0.31%/min gradient of buffer B starting at 20% buffer B. (H) writhing test confirming the nociceptive effect 
of  the major peak of  F28 fraction. i.p.  injection at  2 mg/kg. (I) Mass spectrometry profile of  BotAF as  determined by MALDI-TOF. The molecular weight of  BotAF, indicated by an 
arrow, correspond to the (MþH)þ' ion. 
 
 
According to crude estimations, BotAF represents less than 1%  of 
peptide components of  the BotG50 fraction and less than 0.5% of 
total venom extract. BotAF has an  experimental mass (MþHþ) of 
7419.19 Da  as  determined by  MALDI-TOF   mass  spectrometry 
(Fig. 1I).  This result indicates that BotAF belongs to a long-chain 
class of  scorpion toxins. Amino acid analyses indicate that BotAF 
is pure at 98%. 
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BotAF:  DNGYVLDKYNGCKVCQVINNEACNSECKSRGGyYGYCYFWKLACYCEGANKSELWQYKTNRCRA 
BotAF2:  DNGYVLDKYNGCKVCQVIEACQSECKSRGGTYGYCYFWKLACYCEGANKSELWQYKTNRCRA 
 
Fig. 2. Amino acid sequence  of BotAF and cloning of BotAF2. (A) Partial amino acid sequences  of BotAF as determined by Edman sequencing. (B) C18 analytical HPLC profiles of 
alkylated  BotAF protease  digest  by trypsin  (left panel) or S. aureus V8 protease  (right  panel). (C) eDNA and deduced  amino  acid sequence  of BotAF2 in single letter  code. The 
polyadenylation signal appears in lowercase letters. Underlined nucleotide sequence at the 3' end corresponds  to the adapter sequence of the reverse oligonucleotide. (D) Amino 
acid sequence  alignment  of BotAF and BotAF2. Note that both toxins differ by four amino acids. 
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3.2.  Amino acid  sequence of BotAF and  sequence homology 
 
To   determine the  amino acid sequence  of  BotAF,  5 nmol  of 
peptide was first reduced by 1.4 mmol DTT. The reduced peptide was 
then alkylated with 4-VP (to yield reduced-alkylated BotAF (RA- 
BotAF)), and subjected to direct Edman degradation. A  partial 
sequence was obtained from the N-terminus  up   to amino acid 
position 30 (Fig. 2A). To get additional sequence data, RA-BotAF was 
also separated by SDS-PAGE and gel-digested with either trypsin or 
S.  aureus V8 protease, as  described in  Materials & Methods.  The 
proteolytic peptide fragments from both digests were extracted 
from gel  slices and separated by C18  analytic HPLC (Fig. 2B).  As 
shown, trypsin digestion results into at least 14  major peptide 
fragments (left panel), whereas V8 protease digest yielded at least 
13 fragments (right panel). Fragments T-2,  T-4 and T-8 from trypsin 
digest and fragment V8-6 from V8 protease digest were purified 
and sequenced by Edman degradation. The resulting sequences are 
provided in Fig.  2A.  Sequence overlapping analysis of  the N-term 
sequence of  RA-BotAF,  T-4 and T-2 was used to determine the 
correct order in  the final sequence. T-8 was 7  residues long and 
seems to prolong T-4 sequence to the C-terminus  according to 
sequence homology with BmKAS and BmKAS1  (Fig. 3).  The V8-6 
fragment overlaps and prolongs the T-8 sequence and should 
complete the sequence of  BotAF according to the molecular mass 
obtained.  In   fact  the  theoretical  mass  of   reduced  BotAF  is 
7427.37 Da,   which  should correspond to a  theoretical mass  of 
7419.37 for  folded/oxidized BotAF, a value identical to the experi- 
mental mass obtained. BotAF is therefore a peptide of  64  amino 
acids, presumably containing 4 disulfide bridges. 
To search for  BotAF-like sequences, we therefore undertook the 
cloning and sequencing of cDNAs coding for  BotAF-like toxins. The 
mRNA  was extracted from Bot venomous glands and cDNA  was 
synthesized  by reverse transcription. Resulting cDNAs were PCR- 
amplified with  a   couple  of   predesigned  primers:  a   forward 
primer  designed  on   the  basis  of   the  N-terminal  amino  acid 
sequence of  BotAF and the cDNA  sequence of  three homologous 
toxins,  BmKAS,  BmKAS1  and  BotIT2,   and  a   reverse  oligo dT 
sequence. Amplified PCR products were subcloned into pGEM-T 
vector and sequenced. Several cDNA  sequences were obtained 
coding for   b-like long-chain toxins, but one sequence matched 
more closely what could be  expected for  the cDNA  sequence of 
BotAF (Fig. 2C). It encodes the BotAF2 pro-toxin. The open reading 
frame for  the BotAF2 pro-toxin is 196 bps-long ending with a TGA 
stop codon. A polyadenylation signal is located 157 bps from the 
termination  codon.  Translation  of   this  sequence yields BotAF2 
(Fig. 2D), which differs from BotAF by three amino acids, namely 
Lys19 instead of Asn19, Asp24 instead of Asn24, and Thr33 instead of 
Tyr33.  BotAF2 also contains 64  amino acids and should fold ac- 
cording to the same pattern as BotAF. The predicted molecular mass 
of BotAF2 is 7391.33. 
 
3.3.  BotAF and  BotAF2 are  two new members of the  b-like  long- 
chain scorpion toxins 
 
A  blast  search  was  performed  to  identify  toxins  sharing 
sequence homology with BotAF and BotAF2 sequences. Interest- 
ingly, there is a high homology (>70%) with b-like scorpion toxins 
(BmKAS, BmKAS-1,  BmP09, Lqhb1  and AaHIT4). Multi  sequence 
alignment  for   BotAF  using  ClustalW  software  was  performed 
(Fig. 3A.). Sequence  identities  ranged from 70%  (AaHIT4)  to 78% 
(BmKAS).  ClustalW  alignments  were  also  performed between 
BotAF and depressant anti-insect toxins with characterized anal- 
gesic activity (except for  BotIT2), and results presented in  Fig.  3B 
show that BotAF is sharing also high identity with this group, albeit 
lower (between 43  and 50%). 
3.4.  Toxicity and  rotarod tests 
 
No mortality was noticed 24 h after treatment of  mice by 
increasing doses of BotAF by i.c.v. route (up to 0.5 mmol/kg) or by i.p. 
route (up to 1 mmol/kg).  Since no  external signs of  toxicity were 
observed, we conclude that BotAF exhibits no  toxicity in vivo (see 
Materials & Methods section). 
The  Rotarod experiments  demonstrate  that  BotAF  at   anti- 
nociceptive doses  has no   effect on   motor  function. In  fact,   as 
shown in Fig. 4A, no significant difference is seen between the drop 
latency time in mice groups treated with BotAF (0.5, 1 mmol/kg) i.p. 
or (0.2,  0.5 mmol/kg) i.t. versus control groups (treated with vehicle 
in the same conditions). 
 
3.5.  Anti-nociceptive effect of BotAF in writhing and  hot-plate tests 
 
Using the anti-nociceptive writhing test, BotAF has no  effect 
when injected by i.c.v.   or  i.v.  routes up   to 0.3 mg/kg (data not 
shown). In  contrast, a significant reduction in  acetic acid-induced 
contortions was observed if  BotAF is administered by i.p.  route 
(Fig. 4B).  This effect is dose-dependent and reaches maximum at 
5 mg/kg.  Optimal anti-nociception is observed if BotAF is injected 
i.p. 60 min before the test, but good anti-nociception (up to 50%) is 
still observed 90 min after BotAF administration. A dose-response 
curve was constructed and compared to the effect of  b-endor- 
phine (Fig. 4C). The ED50  of  BotAF is 154.2 nmol/kg (i.p.,  60 min 
before test),  while  that of   b-endorphine  is  358.4 nmol/kg (i.p., 
40 min before test). These results indicate that BotAF is a 2.3-fold 
more potent anti-nociceptive compound than b-endorphine for 
viscero-somatic pain by i.p. administration. 
Next, we evaluated the efficacy of  BotAF on  preventing acute 
somatic nociception by using the hot-plate test (Fig. 4D). BotAF 
dose-dependently attenuates somatic pain by prolonging the paw 
withdrawal latency of C57/BL6 mice to hot plate stimuli. This anti- 
nociceptive activity is dependent on  the time between the treat- 
ment and the nociceptive activity test. The maximum effect occurs 
60 min after i.p.  injection. In  comparison, b-endorphine reaches 
maximal effect 30 min after i.p. injection, but the effect is prolonged 
for more than 1 h after this peak. Dose-response curves illustrate an 
ED50 of 788.4 nmol/kg (i.p., 60 min before test) for BotAF, while that 
of  b-endorphine is 1995 nmol/kg (i.p.,  40 min before test). Here, 
again BotAF is 2.5-fold more efficient than b-endorphine upon i.p. 
injection. In   this  test  also BotAF  has no   effect by i.c.v.   or   i.v. 
injections. 
 
3.6.  Effect of BotAF on  tail-flick test behavior 
 
The i.p.  injection of  BotAF significantly and dose-dependently 
increases the tail  withdrawal latency (Fig. 5A). The maximal anti- 
nociceptive effect is obtained, like  in  the hot-plate test, at  60 min 
after  treatment  and  anti-nociception  is  still  significant  up   to 
120 min after peptide injection. Evaluation of dose-response curves 
provides ED50 of  517.3 nmol/kg for  BotAF (i.p.,  60 min before test), 
while that of  b-endorphine is 2401 nmol/kg (i.p.,  40 min before 
test) (Fig. 5B).  BotAF remains therefore more potent than b- 
endorphine, with  about 4-fold difference this  time. These data 
indicate that there are  not many differences in  efficacy of  BotAF 
with regard to the somatic pain challenged if injected  i.p. 
The analgesic activity was further investigated in this model by 
i.t. injection. Again, a maximal effect of  BotAF on  tail  withdrawal 
latency was observed 60 min after its i.t.  injection (Fig. 5C). This 
effect occurred at lower concentrations than upon i.p.  injections 
(Fig. 5C and D),  and was more transient in  duration. Evaluation of 
the dose-dependence of this effect yields an ED50 of 57.38 hmol/kg 
(60 min before test), which is thus about 9-fold more potent than 
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Fig. 3.  Alignment of  amino acid sequences of  BotAF and BotAF2 with homologous long-chain scorpion toxins. Amino acids are  coloured by % of identity and the typical disulfide- 
bonding pattern of  long-chain peptide toxins is indicated below.  Gaps are  indicated by dashes. BotAF,  BotAF2, and BotIT2 are  from Bot (Buthus occitanus tunetanus); BmKAS, 
BmKAS1, BmKdITAP3, and BmKAEP are  from BmK (Buthus martensi Karsch); Lqhb1 and LqhIT2 are  from Lqh (Leiurus quinquestriatus hebraeus); AaHIT4 is from AaH (Androctonus 
australis hector); LqqIT2 is from Lqq (Leiurus quinquestriatus quinquestriatus). 
 
 
by i.p. administration (Fig. 5D). 
 
3.7.  BotAF antinociceptive effect by i.pl. injection in the  formalin 
test 
 
The intraplantar injection of 2.5% formalin into the left hind paw 
produces a consistent flinch and lifting/licking response in rat. The 
time course curves of  these counted behaviors is biphasic in  time 
(Fig. 6A), comprising two phases: phase 1,  lasting 0e5 min and 
corresponding to acute inflammatory pain and phase 2,  lasting 
10e60 min and corresponding to chronic inflammatory pain. As 
shown  in Fig.   6A,  BotAF  (0.23 mmol/kg  or  0.47   mmol/kg)  intra- 
plantary injected 30 min before formalin, significantly attenuates 
pain behaviors of  both phases 1 and 2  as compared to control 
group. Average flinching scores of BotAF during phase 1 and phase 
2  are  shown in  Fig.  6A and compared to the scores obtained for 
profenid (12 mmol/kg,  i.pl.  30  min before test) and for  morphine 
sulfate (0.6  mmol/kg, i.pl. 30 min before test). As expected, profenid 
produces significant anti-nociception only on the inflammatory 
phase, while morphine sulfate is active on  both phases. 
Dose-response curves of all three compounds, administrated by 
the intraplantar root (i.pl.), are  shown on  both phases except for 
profenid (Fig. 6B).  As shown, the ED50 for  BotAF are  225.7 nmol/kg 
(phase 1)  and 204.9 nmol/kg (phase 2),  while ED50 for  morphine 
sulfate are  552.2 nmol/kg (phase 1) and 442.9 nmol/kg (phase 2). 
These data suggest that BotAF, injected locally, acts as well on phase 
1 than on  phase 2, similarly to morphine sulfate. On average, po- 
tency ratios show that BotAF is more efficient by 2  fold than 
morphine sulfate. 
 
3.8.  Modulation of c-fos/c-jun expression by  BotAF in visceral and 
somatic pain  conditions 
 
As shown, in  Fig.  7, the i.p. injection of  acetic acid,  produces  a 
drastic increase in  c-fos and c-jun mRNA  levels 2 h after viscero- 
somatic pain induction. The i.t. administration of  BotAF dose- 
dependently   inhibits   this   mRNA   expression   increase.  This 
inhibition is complete for c-fos and c-jun. Similarly, using a somatic 
inflammatory  pain  model  (i.pl.    formalin  injection  2 h  before 
assessing mRNA  levels), BotAF pretreatment (i.p.,  15 min before 
formalin injection)  dose-dependently  prevents  c-fos  and  c-jun 
mRNA up-regulations (Fig. 7C and D).  In this model also,  the inhi- 
bition of mRNA level increase is complete for  both c-fos and c-jun. 
Furthermore result in Fig. 7C and D shows that BotAF (0.4  mmol/kg, 
i.p.)  when injected alone (with no  other drug) does not induce any 
significant up-regulation of c-fos and c-jun mRNA level as compared 
to non-treated control group. 
 
3.9.  Pharmacology of BotAF anti-nociceptive activity 
 
The  pharmacological activity  of   BotAF  was  investigated on 
voltage-gated Naþ  currents in  rat  DRG neurons maintained in pri- 
mary cultures. The membrane potential of  rat DRG neurons was 
held at  -80 mV, which was near the resting membrane potential. 
Whole-cell path-clamp recording found that about only 10% of peak 
total sodium currents of  rat DRG neurons could be  significantly 
inhibited by 1 mM of BotAF (Fig. 8A). This inhibition could be largely 
recovered upon washout of  BotAF.  We also assessed the effect of 
1 mM BotAF on the fraction of TTX-resistant currents and the results 
show that BotAF significantly inhibited (about 20%) TTX-R currents 
(data not shown). It is therefore concluded that BotAF is not a good 
Naþ channel blocker and that its anti-nociceptive effect is unlikely 
to involve block of Naþ  channels. 
To  measure the interactions of  BotAF with CNS ion  channels, 
competition binding assays to rat  brain synaptosomes  were per- 
formed with a fixed concentration of  [125I]-BotAF and increasing 
concentrations of BotAF. The results show that BotAF, with and IC50 
of  2.2 mM, has a low affinity for  rat brain synaptosomes  receptors 
(Fig. 8B).   Similarly,  BotAF activity was tested on   ryanodine re- 
ceptors. As shown, 1 mM  BotAF has no  effect on  [3H]-ryanodine 
binding onto SR vesicles (Fig. 8C), indicating that ryanodine re- 
ceptors are  also not good targets for  BotAF. 
The involvement of  the opioid endogenous system in  the anal- 
gesic activity of BotAF was also assessed in the tail  flick  model. We 
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Fig. 4.  Lack of BotAF influence on normal mice motor behaviours and assessment of its analgesic activity by the writhing test and the hot plate test. (A) Rotarod scores of i.p. and i.t. 
BotAF-treated mice compared to control groups (injected by vehicle). (B) Effect of BotAF and b-endorphin in the writhing test. Dose- and time-dependent effect of BotAF. The curves 
were constructed at 40,  60  and 90 min after BotAF administration. (C) Semi-logarithmic representation of dose-response curves for  BotAF and b-endorphin in the writhing test. (D) 
Dose-dependent and time-dependent effect of  BotAF and b-endorphin in the hot-plate test. The curves were constructed at  30,  60,  90  and 120 min after BotAF administration. (E) 
Semi-logarithmic representation of  dose-response curves for  BotAF and b-endorphin in the hot-plate test. 
 
 
studied its possible attenuation by the opioid antagonist naloxone. 
As shown in Fig.  9A,  naloxone pre-treatment does not affect the 
anti-nociceptive activity of  BotAF, assessed in  the tail  flick  model, 
indicating that this peptide does not act  on  opioid receptors for  its 
analgesic effect. 
Finally, the anti-inflammatory activity of BotAF was determined 
in vivo by paw edema volume assessment. Dexamethasone (a well- 
known AINS drug) or BotAF were injected intraplantary 1 h before 
paw edema induction by carrageenan injection. As shown in Fig. 9B, 
only dexamethasone potently inhibited paw inflammation, while 
BotAF injected intraplantary, up  to 1.8 mmol/kg, was ineffective in 
reducing Paw edema volume. 
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Fig. 5.  Characteristics of  BotAF anti-nociceptive effect in the tail-flick test. (A) Dose- and time-dependent effect of  BotAF and b-endorphin in the tail-flick test. i.p. injection of  the 
compounds. (B) Semi-logarithmic representation of  dose-response curves for  BotAF and b-endorphin  in the tail-flick test following i.p.  injection. (C) Dose- and time-dependent 
effect of  BotAF and b-endorphin  in the tail-flick test. i.t.  injection of  the compounds. (D) Semi-logarithmic representation of  dose-response curves for  BotAF and b-endorphin  in 
the tail-flick test following i.t. injection. 
 
 
4.  Discussion 
 
Here, we identified a novel toxin, BotAF,  that produces potent 
analgesic effects in rodents. BotAF was purified from the venom of 
Bot using an  activity-guided screening strategy.  This consisted in 
isolating a compound from Bot  venom fractions by assessing its 
anti-nociceptive effect in vivo together with confirming the lack  of 
toxicity of  the active compound. This strategy requires several 
conditions to be  successful: (i) an  important quantity of  venom 
provided by unique facilities, (ii)  a non-toxic peptide, (ii)  a highly 
active or  sufficiently abundant compound and,  (iii) a reliable (or 
several) pain model(s).  In  this chosen screening approach, the 
writhing test appears adequate since it is highly sensitive test that 
lacks selectivity allowing the identification of  a larger number of 
molecules  regardless of  the pharmacological target involved  in 
nociception. In  addition, to satisfy the exigence of  the screening 
approach, we deliberately focused on  the G-50 venom fractions 
that are devoid of lethality upon i.c.v.  or i.p. injection into mice. As 
most scorpion venom compounds are  toxic, this approach should 
promote the discovery of  original new active compounds. In 
agreement with  this  expectation, we  indeed found BotAF  to 
represent a  minor compound with  less than 1%  of  the venom 
content. This finding also illustrates to which extent the in  vivo 
screening is valid. 
The BotAF sequence was determined by direct sequencing. The 
whole sequence of BotAF consist of 63 amino-acids and the peptide 
has a  MW of  about 7419 Da.  Homology alignments demonstrate 
that BotAF structurally belongs to a family of recently characterized 
toxins, termed b-like scorpion toxins (Gordon et al.,  2003). This 
family contains so far four members, all from the Buthidae family of 
scorpions: BmKAS, BmKAS1 (Lan et al., 1999), AaHIT4 (Loret et al., 
1994) and Lqhb1 (Gordon et al., 2003). These toxins have a mini- 
mum of  70% sequence identity and vary in  length from 63  to 66 
amino acids. The consensus pattern for  disulfide bridges would be 
Cys1-Cys8, Cys2-Cys5, Cys3-Cys6  and Cys4-Cys7. Of relevance to our 
findings, two  members  of   this  family  of   toxins,  BmKAS  and 
BmKAS1, have been reported as efficient analgesics by several tests 
(Chen and Ji, 2002; Chen et al., 2006; Shao et al., 2008). BotAF has 
also a level of  sequence identity (between 43  and 50%)  with anti- 
insect depressant toxins such as  BmKAEP (an  analgesic and anti- 
epileptic toxin). Several other members of  the anti-insect depres- 
sant toxin family have analgesic properties as  well (Guan et al., 
2001; Bai   et al.,  2007). We  reveal also very limited sequence 
identities with members of  the b-toxin  family,  known for  their 
toxicity in vivo.  Beside its analgesic potential, the so-called beta-like 
toxin  group shows  several original features compared to other 
scorpions groups as it is composed by a restricted set of members 
sharing high sequence similarities but also peculiar and diverse 
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Fig. 6.  Anti-nociceptive  effect of  BotAF in the formalin test. (A) Effect of  BotAF on 
averaged flinching scores for  each phase: acute phase (phase 1) and an  inflammatory 
phase (phase 2),  compared to the effects of  saline, profenid and morphine sulfate. (B) 
Dose-response curves of all tested compounds on both phases, except for  profenid that 
was evaluated on phase 2 exclusively. 
 
 
pharmacological profiles. Thus, BotAF constitutes  by itself a very 
promising  lead for  future structure-function  studies and for  un- 
derstanding the evolution of scorpion's toxins. 
As BotAF seems to have a promising pharmacological profile, it 
seemed of interest to search for  analogues within the same venom 
as alternative splicing of genes coding for toxins is a frequently used 
strategy to enrich the repertoire of active compounds. The success 
of  this approach was exemplified herein by molecular biology as 
toxin cloning from Bot venomous glands provided the sequence of a 
new BotAF isoform, termed herein BotAF2. BotAF2 differs from 
BotAF by only three amino acid residues and is therefore likely to 
possess the same anti-nociceptive effect than BotAF itself. Never- 
theless, this assumption can   be  proven true only when the full 
synthesis of  BotAF2 will be  performed chemically or  through re- 
combinant means. For  the time being, we did  not find out in which 
fraction of the venom BotAF2 was present, possibly also because it 
also represents a minor component of  the venom. 
Our work also attempted to deepen the in vivo activity of BotAF. 
Toxicity of  the molecule was investigated by means of  lethality 
assessment  after 48 h and by direct observation of  any mice 
behavioral change that could reflect a form of  intoxication sum- 
marized in bibliographic data in which these symptoms were well 
characterized (Ozkan et al., 2007; Pipelzadeh et al., 2015). Besides 
toxicity, it was also important to assess animal motor response in 
BotAF administration condition. Many  pain models used for 
investigating nociception in conscious laboratory animals rely upon 
an  observable motor response and the analgesic potential is eval- 
uated on  the basis of  changes in  the latency of  motor responses 
following nociceptive stimulation (heat, acetic acid…). Interpreta- 
tion of  an  increase in  response latency as  evidence that analgesia 
takes place is invalid if the putative analgesic factor interferes with 
motor function (Warren and Lson, 1982). Such confounding motor 
effects can  be  assessed in  many ways, including the rotarod test. 
Thus, we used this particular test to measure whether or not BotAF 
affects the motor coordination of rodents over the time periods and 
experimental conditions used in  revealing its antinociceptive ac- 
tivity. Using this procedure, we confirmed that behavioral changes 
in  mice challenged with BotAF was not due to impairment of  the 
normal motor function but to its anti-nociceptive action. 
Next,  the potency and specificity of  the analgesic activity of 
BotAF was analyzed, first in vivo by assessment of animal behavioral 
changes in several pain models, and,  secondly, in vitro by assessing 
nociceptors  activation. We   started  with  acute  pain  models: 
writhing test (model designed for  visceral pain), hot plate test and 
tail  flick  test (somatic pain). In those models, BotAF shows a potent 
preemptive  analgesia (with  an   optimal activity obtained when 
injected 1 h before pain induction) as  confirmed by ED50  values 
compared to b-endorphine as  a reference analgesic drug. In  addi- 
tion, BotAF analgesic activity was further investigated on  an  in- 
flammatory pain model: the formalin test. The data demonstrate 
that BotAF is efficient towards abolishing inflammatory pain with 
high potency compared to profenid and morphine-sulfate. The 
interesting potent analgesia of  BotAF in  all  tested models is 
particularly informative when considering the different pain syn- 
drome that they represent.  In fact,   such lack  of  specificity for  a 
particular pain type (visceral/somatic/acute/inflammatory…) is in 
favor of  an  action of  BotAF on  the nerve conduction  and/or the 
central transmission of  pain information rather than on  the pain 
induction processes themselves (stimulus transduction). In  this 
context, it is worth reminding that the analgesic efficacy of  other 
reported venom peptides is dependent on  their mode of  adminis- 
tration. This, in  turn, has often limited their clinical use (see for 
instance Prialt restricted to i.t.  injection (Rauck et al., 2009)), or 
restrained their usage to a preclinical level. Concerning  BotAF,  it 
was ineffective by the i.c.v.  or i.v. roots. Conversely, the compound 
was highly effective when administrated by the i.t. root regardless 
of  the pain etiology. It should therefore face similar challenges for 
the clinical applications as  Prial.  However,  contrary to the later, 
BotAF shows a gain in potency in  the formalin test when injected 
intrapodally which  should facilitate to some extent  its  clinical 
application. 
The analgesic activity of BotAF was further evaluated in vitro by 
quantifying medullar c-fos and c-jun mRNA  expression. Painful 
visceral (acetic acid in peritonea) or somatic stimuli (intrapodal 
formalin injection) leads to a rapid and transient induction of  the 
expression of  the immediate early genes c-fos and c-jun in lumbar 
spinal cord (Barr et al.,  2003; Bianchi et al.,  2003). The level of 
expression of these immediate early genes is reflective of the spinal 
activation by the nociceptive input and is used therefore as an  in- 
direct marker of  pain (Morgan and Curran, 1991).  As expected, 
BotAF attenuates in  a  dose-dependent  manner the induction of 
pain-related expression of both c-fos and c-jun. These observations 
were previously also reported for  other analgesic scorpion toxins 
(Bai et al., 2007; Liu  et al., 2008; Martin-Eauclaire et al., 2010). Also, 
the amount of  Fos/Jun mRNA  expression inhibition is correlated 
with the potency of  analgesia. Several studies have shown that 
analgesics, given preemptively, reduce the extent of Fos expression 
in  a dose-dependent manner with a good correlation with their 
potency (Abbadie et al., 1994; Abbadie and Besson, 1994).  Hence, 
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Fig. 7.  BotAF modulation of  c-fos and c-jun increased expression by acetic acid or  formalin. (A.1)  BotAF dose-dependent inhibition of  the acetic acid-induced increase in c-fos 
expression. i.p. injection of BotAF 1 h before acetic acid treatment. (A.2) BotAF dose-dependent inhibition of  the acetic acid-induced increase in c-jun expression. Similar conditions 
as  in (A.1).  (B.1) BotAF dose-dependent inhibition of  the formalin-induced increase in c-fos expression. i.p.  injection of  BotAF 1 h before formalin treatment. (B.2) BotAF dose- 
dependent inhibition of  the formalin-induced increase in c-jun expression. Similar conditions as  in (B.1.). For all  experiments, data were expressed as  mRNA c-fos/mRNA GAPDH 
ratio or  mRNA c-jun/mRNA GAPDH ratio. 
 
 
evaluation of  the extent of  spinal mRNA inhibition levels of  these 
oncogenes further confirms the analgesic potency of  BotAF (pre- 
viously demonstrated by in vivo ED50 values analysis) since it fully 
abolished their expression levels. 
Finally, several experiments have been performed to identify or 
rule out some specific molecular pharmacological targets of BotAF. 
We investigated some of  the proposed targets of  BotAF structural 
toxin analogues that were described to possess analgesic activity: 
beta like  scorpion toxins and depressant insect toxins (Guan et al., 
2001). Pharmacological targets of  the b-like scorpion toxin family 
include TTX-resistant and TTX-sensitive  voltage-gated Naþ  chan- 
nels (Chen et al., 2006; Zhu et al., 2009). Apart from Naþ channels, 
the group of Ji (Tan et al., 2001) showed that BmKAS1 inhibits [3H]- 
ryanodine binding on  skeletal muscle by an  indirect mechanism. 
Although Naþ  channels constitute more relevant pharmacological 
targets for  analgesic activity than ryanodine receptors, it should be 
stressed out that b-like scorpion toxins have weak affinities for Naþ 
channels. In fact,  in  brain synaptosomes, BotAF binds onto a weak 
affinity target, which is coherent with its lack  of  i.c.v.  toxicity. We 
have also detected a limited activity of BotAF towards voltage-gated 
Naþ channels of DRG neurons and no  activity at all onto ryanodine 
receptors. A more profound block of  TTX-resistant Naþ  channels 
was found suggesting that among the various members of voltage- 
gated Na
þ 
channels, BotAF may preferentially target TTX-resistant 
Naþ channels, although these findings are  not very conclusive for 
the moment. It should be noted that the DRG neuron TTX-R sodium 
channels has been demonstrated to be  the most promising targets 
for  analgesics (Silos-Santiago, 2008). Although our  results are 
coherent with the effects of  other members of  the same family of 
toxins, the weak level of  current inhibition and the relatively low 
affinity for  this effect questions whether voltage-gated Naþ chan- 
nels are  the real  pharmacological target whereby the potent anal- 
gesic effect of  BotAF occurs. While several studies implicate 
ryanodine  receptors  in   nociception, BotAF obviously lacks the 
ability to bind to ryanodine receptors contrary to the homologous 
toxins, BmKAS and AS1.  For  the depressant insect toxins group, 
another mechanism of  anti-nociception was proposed: release of 
endogenous opioids. This is also not the case of  BotAF where 
naloxone fails to antagonize the analgesic activity of  BotAF.  Thus, 
we conclude that more detailed investigations are  warranted to 
identify the real  pharmacological targets of BotAF. 
With regard to the analgesic effects of BotAF, several features are 
worth discussion. First, BotAF is active on  acute somatic pain (hot- 
plate  and  tail-flick  models),   on    inflammatory  somatic   pain 
(formalin test), and on  inflammatory visceral pain (writhing test). 
This indicates that BotAF acts through molecular targets that play a 
key role  in  conduction and transmission of  different nociceptive 
information rather than on pain transduction. Second, the mode of 
action of  BotAF does not involve opioid receptors or  an  AINS-like 
mechanism,  clearly  distinguishing  this  molecule  from  these 
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Fig. 8.  Pharmacology of  BotAF.  (A) Representative effect of  1 mM  BotAF on voltage- 
gated Na
þ  
currents from isolated DRG neurons and mean inhibition. (B) Competitive 
displacement of  [
125
I]-BotAF binding by unlabeled BotAF onto rat  brain synaptosomes. 
(C) Effect of  BotAF on [
3
H]-ryanodine binding compared to the effect of  maurocalcine. 
 
 
common classes of  analgesics. Third, the observation that BotAF 
prevents the increase in c-jun or c-fos under various pain stimuli is 
indicative that BotAF prevents the electrical activity of nociceptive 
neuronal  afferents. This  observation  is  in   line  with  the  data 
 
 
 
Fig. 9.  BotAF does not act  through an  opioid receptor and has no anti-inflammatory 
activity.    (A)   Naloxone   and  naloxone  methiodide  modulation  of    BotAF  anti- 
nociceptive effect in the tail-flick test. (B) BotAF effect on the Carrageenan-induced 
oedema in the rat. 
 
 
suggesting that the anti-nociceptive effect of BotAF is not mediated 
by a supra-spinal effect. In  that respect, it is informative that the 
anti-nociceptive efficacy of  BotAF is reliant on  the mode of 
administration. The i.c.v.  route was not efficient for  analgesia in all 
pain models used in  this study.  Conversely,  i.t. injection of  BotAF 
was the most efficient mode of administration, at least in the pain 
model tested (tail-flick model). The intraplantar injection revealed 
itself also very efficient for  the formalin test. Similarly, the i.p. in- 
jection was found more potent for  the writhing test than the other 
modes of  administration. These data indicate that the peripheral 
action of  BotAF is best when locally administered at  the same 
compartment than where the nociception generates. Altogether, 
these observations argue in  favor of  a  peripheral and/or spinal 
mechanism for  BotAF activity. 
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